301060.SZ
兰卫医学
SZSE · Healthcare · F 批发零售 · CN
CNY 11.43
−0.61%Year over year
Reported trailing growth
- Revenue
- -16.4%
- EBITDA
- —
- EBIT
- +186.2%
- EPS
- +109.8%
- Free cash flow
- +71.6%
- Operating cash flow
- +43.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -29.9%
- EBITDA
- -53.2%
- EBIT
- -75.0%
- Net income
- +71.9%
- EPS
- +70.4%
- Free cash flow
- +19.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026